Quest Diagnostics Updates 2016 Revenue Outlook - Quick Facts

(RTTNews) - Quest Diagnostics (DGX) announced the company expects 2016 revenue, before special items, to be between $7.47 billion and $7.54 billion, an increase of 2% to 3% over 2015 on an equivalent basis. Previous revenue guidance, which included the Focus Diagnostics products business, was between $7.52 billion and $7.59 billion.

The company continues to expect adjusted EPS excluding amortization to be between $5.02 and $5.17.

Quest Diagnostics also announced it has completed efforts to refocus its business on diagnostic information services following the completion of the sale of its Focus Diagnostics products business to DiaSorin S.p.A. for $300 million in cash. The company plans to use the proceeds of the Focus Diagnostics transaction to repurchase Quest Diagnostics common stock.